Eris Lifesciences · NSE: ERIS · BSE: 540596

Q2 FY26 results · Jul–Sep 2025

Eris Lifesciences reported revenue from operations of ₹792.41 crore (up 7.2% from Q2 FY25) and net profit of ₹134.47 crore (up 39.6% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	792.41	738.95	+7.2%	773.00	+2.5%
Other income	2.81	6.77	−58.5%	2.69	+4.5%
Total income	795.22	745.72	+6.6%	775.69	+2.5%
Profit before share of associates & JVs and tax	172.39	129.11	+33.5%	160.21	+7.6%
Share of profit/(loss) of associates & JVs	0.28	0.00		0.89
Net profit for the period	134.47	96.35	+39.6%	125.10	+7.5%
Attributable to shareholders of the company	120.19	91.59	+31.2%	117.99	+1.9%
EPS, basic (₹)	8.82	6.73	+31.1%	8.66	+1.8%
Net margin (%)	17.0	13.0		16.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	650.50	428.75	+51.7%	578.64	+12.4%
Other income	23.59	13.62	+73.2%	22.68	+4.0%
Total income	674.09	442.37	+52.4%	601.32	+12.1%
Profit before tax	234.67	46.02	+409.9%	156.26	+50.2%
Net profit for the period	149.57	28.10	+432.3%	99.99	+49.6%
EPS, basic (₹)	10.98	2.06	+433.0%	7.34	+49.6%
Net margin (%)	23.0	6.6		17.3

Consolidated

Filed with BSE: 12 Nov 2025, 18:39 IST
Board meeting: 12 Nov 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 12 Nov 2025, 18:39 IST
Board meeting: 12 Nov 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE